Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Jul 25, 2022 12:17pm
89 Views
Post# 34848366

RE:RE:I spoke with LaFond this morning

RE:RE:I spoke with LaFond this morningBTW the gain is taxable on only 50% of the capital gain 
palinc2000 wrote: He noted he got burned financially in the past exercising previous options and paying the taxes out of his pocket, so once burned twice shy

That statement is not supported by his filings on Sedi ever since he becamean insider.....Unless he meant with an other public company but nothing shows up on Sedi....Did he lie to you? I hope not

SPCEO1 wrote: Our new head of IR kindly put together a quick call with Jocelyn, which was appreciated given the negative impact of this news. 

Jocelyn indicated these options are part of their compensation package and he was just selling them to add to his compensation and because the expration data is not far off. He greatly regrets not exercising them when the stock hit its high in 2018 (I told him we can all relate to that, unfortunately). When asked about the timing in light of the potential for additional good phase 1b cancer news coming before the 12/20/22 expiration of these very low cost options, he really did not address that. He noted the trading volume is low so maybe he did not want to be in a position where he exercised them on the last day and then sold into a low volume market? But there are ways to handle that.

Obviously, these are very low cost shares and the 53% tax hit is huge. So, the most bullish response is an executive excercises low cost options, pays his huge taxes out of his pocket and holds onto all of the shares. The next best option for investors like us is to see him only sell the amount of shares needed to cover the tax hit. The worst option is to see all the exercised shares be sold, which is what we have in this case. Offsetting thsi clear negative is Jocelyn has not sold off his 18,000 shares he currently owns outright (not option exposure). He noted he got burned financially in the past exercising previous options and paying the taxes out of his pocket, so once burned twice shy?

So, there is no way around the fact that this does not look great. Only Jocelyn and Christian still own these very low cost options given out many years ago when the company was hanging on by a thread. Jocelyn has 105,000 left and Christian still has 125,000 left. My impression is we will see more filings from Jocelyn in the days to come and we obviously will see all of these options exercised sometime between now and 12/20/22. So, all eyes are now on Christian - if he exercises and sells before any new cancer development, that will be an even worse look than this. If he exercises, pays the taxes out of his own pocket and holds the shares, that would be a very bullish look. 

Right now, however, we have the first insider sale in several years coming right after good news on cancer and no insider buying. It is not a good look. Christian - we await your next move. Paul, Philippe, the board - the lack of buying is now deafening. THTX's main problem with investors is the lack credibility and unless there is some insider buying soon, Elif's job just got even harder to rebuild that lost credibility. 




<< Previous
Bullboard Posts
Next >>